Management Team
Location:Home > About us > Management Team

Kanyin E. Zhang, Ph.D., CEO and Cofounder


     Dr. Kanyin E. Zhang has more than 20 years of experience in drug discovery and development from both US and China. Kanyin began his pharmaceutical research career in the US and held various positions from Research Scientist to Director of DMPK/Pharmacology at Merck, Agouron/Pfizer, and GNF (Genomics Institute of the Novartis Research Foundation), and involved in the development of two marketed products and a dozen clinical candidates. In 2007, Kanyin returned to China to further his career in both science and business. He joined Argusina Biosciences, a drug discovery startup founded by Morningside, as a founding member and served as the general manager at its Shanghai R&D center. Kanyin received his Ph.D. degree from the School of Pharmacy at the University of Washington, Seattle.
    Kanyin also serves as a Board of Director of Aranda Pharma Ltd.



Xiaokun Zhang, Ph.D., Cofounder and Chief Scientific Advisor


     Dr. Xiao-kun Zhang is the Dean of School of Pharmaceutical Sciences at the Xiamen University and Professor of the Sanford-Burnham Medical Research Institute, California. He is among the first group of recipients of the China 1000 talent program. Throughout his career, he has devoted his research in the chemopreventive and therapeutic effects of nuclear receptors. He discovered a new vitamin A signaling pathway through nuclear receptor RXR protein complexes. As a result, Targretin, a small molecule ligand that activates RXR, was identified and approved by the FDA for treating Cutaneous T-Cell Lymphoma. Subsequent research by his team has led to the discovery of truncated RXRα (tRXRα) as a novel target for cancer therapeutics and TX803 that targets this cancer promoting protein. Xiaokun received his Ph.D. degree from the University of Vermont in 1989. He is a co-inventor of 9 US and 7 Chinese patents and co-author of 120 peer-reviewed publications.